B
0.802
0.00 (0.10%)
| Previous Close | 0.801 |
| Open | 0.820 |
| Volume | 40,270 |
| Avg. Volume (3M) | 182,541 |
| Market Cap | 12,492,615 |
| Price / Sales | 0.440 |
| Price / Book | 5.44 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2024 |
| Profit Margin | -110.55% |
| Operating Margin (TTM) | -141.73% |
| Diluted EPS (TTM) | -0.710 |
| Quarterly Revenue Growth (YOY) | -23.00% |
| Total Debt/Equity (MRQ) | 92.48% |
| Current Ratio (MRQ) | 0.550 |
| Operating Cash Flow (TTM) | -6.56 M |
| Levered Free Cash Flow (TTM) | -2.98 M |
| Return on Assets (TTM) | -88.58% |
| Return on Equity (TTM) | -290.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | bioAffinity Technologies, Inc. | Mixed | - |
AIStockmoo Score
-1.1
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.13 |
|
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company’s product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 24.53% |
| % Held by Institutions | 1.80% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |